Abstract

Cancer cells exhibit specific physiological differences compared to normal cells. Most surface membranes of cancer cells are characterized by high expression of given protein receptors, such as albumin, transferrin, and growth factors that are also present in the plasma of patients themselves, but are lacking on the surface of normal cells. These distinct features between cancer and normal cells can serve as a niche for developing specific treatment strategies. Near-infrared (NIR)-light-triggered therapy platforms are an interesting novel avenue for use in clinical nanomedicine. As a photothermal agent, conducting polymer nanoparticles, such as polypyrrole (PPy), of great NIR light photothermal effects and good biocompatibility, show promising applications in cancer treatments through the hyperthermia mechanism. Autologous plasma proteins coated PPy nanoparticles for hyperthermia therapy as a novel core technology platform to treat cancers through secreted protein acid and rich in cysteine targeting are developed here. This approach can provide unique features of specific targeting toward cancer cell surface markers and immune transparency to avoid recognition and attack by defense cells and achieve prolonged circulation half-life. This technology platform unveils new clinical options for treatment of cancer patients, supporting the emergence of innovative clinical products.

Original languageEnglish
JournalAdvanced healthcare materials
DOIs
Publication statusPublished - 2017

Fingerprint

Blood Proteins
Cells
Polypyrroles
Proteins
Plasmas
Hyperthermia therapy
Nanoparticles
Infrared radiation
Medical nanotechnology
Neoplasms
Oncology
Conducting polymers
Transferrin
Biocompatibility
Transparency
Cysteine
Albumins
Intercellular Signaling Peptides and Proteins
Therapeutics
Fever

Keywords

  • Photodynamic therapy
  • Plasma proteins
  • Polypyrrole nanocomplexes
  • SPARC
  • Targeting colon cancer cells

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Pharmaceutical Science

Cite this

Self-Targeting, Immune Transparent Plasma Protein Coated Nanocomplex for Noninvasive Photothermal Anticancer Therapy. / Mi, Fwu Long; Burnouf, Thierry; Lu, Shih Yuan; Lu, Yu Jen; Lu, Kun Ying; Ho, Yi Cheng; Kuo, Chang Yi; Chuang, Er Yuan.

In: Advanced healthcare materials, 2017.

Research output: Contribution to journalArticle

@article{99d0d041664043c1bdea467337923724,
title = "Self-Targeting, Immune Transparent Plasma Protein Coated Nanocomplex for Noninvasive Photothermal Anticancer Therapy",
abstract = "Cancer cells exhibit specific physiological differences compared to normal cells. Most surface membranes of cancer cells are characterized by high expression of given protein receptors, such as albumin, transferrin, and growth factors that are also present in the plasma of patients themselves, but are lacking on the surface of normal cells. These distinct features between cancer and normal cells can serve as a niche for developing specific treatment strategies. Near-infrared (NIR)-light-triggered therapy platforms are an interesting novel avenue for use in clinical nanomedicine. As a photothermal agent, conducting polymer nanoparticles, such as polypyrrole (PPy), of great NIR light photothermal effects and good biocompatibility, show promising applications in cancer treatments through the hyperthermia mechanism. Autologous plasma proteins coated PPy nanoparticles for hyperthermia therapy as a novel core technology platform to treat cancers through secreted protein acid and rich in cysteine targeting are developed here. This approach can provide unique features of specific targeting toward cancer cell surface markers and immune transparency to avoid recognition and attack by defense cells and achieve prolonged circulation half-life. This technology platform unveils new clinical options for treatment of cancer patients, supporting the emergence of innovative clinical products.",
keywords = "Photodynamic therapy, Plasma proteins, Polypyrrole nanocomplexes, SPARC, Targeting colon cancer cells",
author = "Mi, {Fwu Long} and Thierry Burnouf and Lu, {Shih Yuan} and Lu, {Yu Jen} and Lu, {Kun Ying} and Ho, {Yi Cheng} and Kuo, {Chang Yi} and Chuang, {Er Yuan}",
year = "2017",
doi = "10.1002/adhm.201700181",
language = "English",
journal = "Advanced healthcare materials",
issn = "2192-2640",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Self-Targeting, Immune Transparent Plasma Protein Coated Nanocomplex for Noninvasive Photothermal Anticancer Therapy

AU - Mi, Fwu Long

AU - Burnouf, Thierry

AU - Lu, Shih Yuan

AU - Lu, Yu Jen

AU - Lu, Kun Ying

AU - Ho, Yi Cheng

AU - Kuo, Chang Yi

AU - Chuang, Er Yuan

PY - 2017

Y1 - 2017

N2 - Cancer cells exhibit specific physiological differences compared to normal cells. Most surface membranes of cancer cells are characterized by high expression of given protein receptors, such as albumin, transferrin, and growth factors that are also present in the plasma of patients themselves, but are lacking on the surface of normal cells. These distinct features between cancer and normal cells can serve as a niche for developing specific treatment strategies. Near-infrared (NIR)-light-triggered therapy platforms are an interesting novel avenue for use in clinical nanomedicine. As a photothermal agent, conducting polymer nanoparticles, such as polypyrrole (PPy), of great NIR light photothermal effects and good biocompatibility, show promising applications in cancer treatments through the hyperthermia mechanism. Autologous plasma proteins coated PPy nanoparticles for hyperthermia therapy as a novel core technology platform to treat cancers through secreted protein acid and rich in cysteine targeting are developed here. This approach can provide unique features of specific targeting toward cancer cell surface markers and immune transparency to avoid recognition and attack by defense cells and achieve prolonged circulation half-life. This technology platform unveils new clinical options for treatment of cancer patients, supporting the emergence of innovative clinical products.

AB - Cancer cells exhibit specific physiological differences compared to normal cells. Most surface membranes of cancer cells are characterized by high expression of given protein receptors, such as albumin, transferrin, and growth factors that are also present in the plasma of patients themselves, but are lacking on the surface of normal cells. These distinct features between cancer and normal cells can serve as a niche for developing specific treatment strategies. Near-infrared (NIR)-light-triggered therapy platforms are an interesting novel avenue for use in clinical nanomedicine. As a photothermal agent, conducting polymer nanoparticles, such as polypyrrole (PPy), of great NIR light photothermal effects and good biocompatibility, show promising applications in cancer treatments through the hyperthermia mechanism. Autologous plasma proteins coated PPy nanoparticles for hyperthermia therapy as a novel core technology platform to treat cancers through secreted protein acid and rich in cysteine targeting are developed here. This approach can provide unique features of specific targeting toward cancer cell surface markers and immune transparency to avoid recognition and attack by defense cells and achieve prolonged circulation half-life. This technology platform unveils new clinical options for treatment of cancer patients, supporting the emergence of innovative clinical products.

KW - Photodynamic therapy

KW - Plasma proteins

KW - Polypyrrole nanocomplexes

KW - SPARC

KW - Targeting colon cancer cells

UR - http://www.scopus.com/inward/record.url?scp=85019169166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019169166&partnerID=8YFLogxK

U2 - 10.1002/adhm.201700181

DO - 10.1002/adhm.201700181

M3 - Article

JO - Advanced healthcare materials

JF - Advanced healthcare materials

SN - 2192-2640

ER -